{"entity": "journal", "iuid": "b81769cedb534679b36a2e064459cca3", "timestamp": "2026-09-26T22:59:04.652Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/journal/Cardiooncology.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/journal/Cardiooncology"}}, "title": "Cardiooncology", "issn": "2057-3804", "issn-l": null, "publications_count": 2, "publications": [{"entity": "publication", "iuid": "8a8d3ab2bd9b45759a978b2aebd5bd11", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/8a8d3ab2bd9b45759a978b2aebd5bd11.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/8a8d3ab2bd9b45759a978b2aebd5bd11"}}, "title": "Exploratory study linking plasma proteomics to cardiotoxicity in Hodgkin lymphoma.", "authors": [{"family": "Ulfstedt", "given": "Johan Mattsson", "initials": "JM"}, {"family": "Risebro", "given": "Ragnhild", "initials": "R"}, {"family": "Freyhult", "given": "Eva", "initials": "E"}, {"family": "Christersson", "given": "Christina", "initials": "C"}, {"family": "M\u00f6rth", "given": "Charlott", "initials": "C"}, {"family": "Kamali-Moghaddam", "given": "Masood", "initials": "M"}, {"family": "Robelius", "given": "Anna", "initials": "A"}, {"family": "Enblad", "given": "Gunilla", "initials": "G"}, {"family": "Molin", "given": "Daniel", "initials": "D"}], "type": "journal article", "published": "2025-12-26", "journal": {"title": "Cardiooncology", "issn": "2057-3804", "volume": "12", "issue": "1", "pages": "13", "issn-l": null}, "abstract": "BACKGROUND: Cardiovascular toxicity is a well-known complication of chemotherapy, especially doxorubicin (DXR), and irradiation of the mediastinum for classical Hodgkin lymphoma (cHL). Due to the excellent prognosis in cHL, the mortality rate in late toxicity historically exceeds that of relapse of lymphoma. This highlights the need for strategies to minimize toxicity.Our aim was to characterize the prevalence of cardiovascular diseases (CVDs) in our cohort of cHL patients treated with DXR with or without radiotherapy according to standard practice and to identify any plasma protein associations with preexisting or emerging CVD posttreatment. METHODS: We analyzed 182 different proteins in plasma samples from 56 cHL patients and 60 controls using Olink multiplex protein panels Oncology II and Cardiovascular III. The analysis was supplemented with separate analyses of N-terminal pro-brain natriuretic peptide (NTpro-BNP), troponin I and C-reactive protein (CRP). The patient samples were prospectively collected prior to, during and after treatment. RESULTS: Our analysis revealed a statistically significant association between the compound endpoint of heart failure and ischemic heart disease and the protein biomarkers cysteine rich protein 61 (CYR61), glycoprotein nonmetastatic melanoma protein B (GPNMB) and activated leukocyte cell adhesion molecule (ALCAM) in samples collected after treatment for cHL. CONCLUSION: This exploratory study identified three new biomarkers reflecting different biological processes associated with CVD in patients treated for cHL. Adding biomarkers to risk prediction in this population has the potential to identify patients with a high risk of cardiovascular events who need focused follow-up.", "doi": "10.1186/s40959-025-00426-2", "pmid": "41449437", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC12853685"}, {"db": "pii", "key": "10.1186/s40959-025-00426-2"}], "notes": [], "created": "2026-09-23T15:58:51.025Z", "modified": "2026-09-23T15:58:51.056Z"}, {"entity": "publication", "iuid": "a702f70f4cc84274a9baaf8ace269561", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/a702f70f4cc84274a9baaf8ace269561.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/a702f70f4cc84274a9baaf8ace269561"}}, "title": "Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma.", "authors": [{"family": "M\u00f6rth", "given": "Charlott", "initials": "C", "orcid": "0000-0002-2308-6666", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/b2962a416b32416d9e3c2454f1e832b2.json"}}, {"family": "Sabaa", "given": "Amal Abu", "initials": "AA"}, {"family": "Freyhult", "given": "Eva", "initials": "E"}, {"family": "Christersson", "given": "Christina", "initials": "C"}, {"family": "Hashemi", "given": "Jamileh", "initials": "J"}, {"family": "Hashemi", "given": "Nashmil", "initials": "N"}, {"family": "Kamali-Moghaddam", "given": "Masood", "initials": "M"}, {"family": "Molin", "given": "Daniel", "initials": "D"}, {"family": "H\u00f6glund", "given": "Martin", "initials": "M"}, {"family": "Eriksson", "given": "Anna", "initials": "A"}, {"family": "Enblad", "given": "Gunilla", "initials": "G"}], "type": "journal article", "published": "2021-02-03", "journal": {"title": "Cardiooncology", "issn": "2057-3804", "volume": "7", "issue": "1", "pages": "6", "issn-l": null}, "abstract": "Cardiovascular toxicity is a notorious complication of doxorubicin (DXR) therapy for diffuse large B-cell lymphoma (DLBCL). Although surveillance of well-known biological markers for cardiovascular disease (CVD) as NTproBNP and Troponins may be helpful, there are no established markers to monitor for evolving CVD during treatment. New possibilities have arisen with the emergence of newer techniques allowing for analysis of plasma proteins that can be associated with cardiovascular disease. Proximity Extension Assay is one of them.\n\nWe aimed to illustrate the incidence of CVD in DLBCL patients treated with DXR and to establish whether there are plasma proteins associated with pre-existing or emerging CVD.\n\nIn 95 patients, 182 different proteins from OLINK panels, NTproBNP, Troponin I and CRP were assessed prior to, during and after treatment. For comparison, samples from controls were analyzed.\n\nIn the DLBCL cohort, 33.3% had pre-treatment CVD compared to 5.0% in the controls and 23.2% developed new CVD. Of the 32.6% who died during follow up, CVD was the cause in 4 patients. Spondin-1 (SPON-1) correlated to pre-treatment CVD (1.22 fold change, 95% CI 1.10-1.35, p = 0.00025, q = 0.045). Interleukin-1 receptor type 1 (IL-1RT1) was associated to emerging CVD (1.24 fold change, 95% CI 1.10-1.39, p = 0.00044, q = 0.082).\n\nWe observed a higher prevalence of CVD in DLBCL patients compared to controls prior to DXR therapy. Two proteins, SPON-1 and IL-1RT1, were related to pre-existing and emerging CVD in DXR treated patients. If confirmed in larger cohorts, IL-1RT1 may emerge as a reliable biomarker for unfolding CVD in DLBCL.", "doi": "10.1186/s40959-021-00092-0", "pmid": "33536059", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC7856776"}, {"db": "pii", "key": "10.1186/s40959-021-00092-0"}], "notes": [], "created": "2026-09-23T11:21:28.197Z", "modified": "2026-09-23T11:21:28.306Z"}], "created": "2026-09-23T11:21:28.262Z", "modified": "2026-09-23T11:21:28.262Z"}